№ files_lp_3_process_7_070091
File format: docx
Character count: 5040
File size: 94 KB
Year:
2023
Region / city:
United Kingdom
Topic:
Medicine optimisation, diabetes, heart failure, chronic kidney disease
Document type:
Protocol
Organisation:
NHS England
Author:
Not specified
Target audience:
Healthcare professionals
Period of validity:
Ongoing
Approval date:
September 25, 2023
Modification date:
Not specified
Clinical condition:
Type 2 diabetes mellitus, heart failure, chronic kidney disease
Medication:
Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin
Intended use:
Generic dapagliflozin
Switch criteria:
Based on patient needs and clinical appropriateness
Inclusion criteria:
Patients aged 18 years and older currently prescribed certain SGLT2 inhibitors
Exclusion criteria:
History of adverse reactions or specific clinical conditions
Recommended dosage:
10mg once daily, with adjustments for hepatic or renal impairment
Monitoring:
HbA1c, blood tests, signs of infections or DKA
Drug interactions:
Fewer interactions compared to other SGLT2 inhibitors
Patient communication:
Information leaflets, SMS, letters
Post-switch monitoring:
Routine HbA1c checks, watch for DKA
Clinical recommendation:
Consider shared decision-making and patient discussions
References:
NICE guidelines, NHS guidance, formulary recommendations
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines Optimisation, SGLT2 inhibitors
Document Type:
Protocol
Author:
NHS England
Target Audience:
Healthcare professionals, clinicians, systems involved in diabetes and heart failure treatment
Period of Validity:
Ongoing
Approval Date:
September 25, 2023
Date of Changes:
Not specified
Clinical Area:
Type 2 diabetes, heart failure, chronic kidney disease
Inclusion Criteria:
Patients aged 18 years and older prescribed empagliflozin, canagliflozin, ertugliflozin, or branded dapagliflozin for T2DM and/or HF
Exclusion Criteria:
Severe renal impairment, diabetic ketoacidosis, and other contraindications as per SPC
Background:
Dapagliflozin is now the first-line SGLT2i in England due to cost reduction following patent expiry.
Implementation Date:
Not specified
Post-switch:
No need for additional eGFR monitoring unless clinical concerns arise
Description:
Protocol outlining the process for switching eligible patients from other SGLT2 inhibitors to dapagliflozin for the management of Type 2 diabetes and heart failure in primary care.
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines Optimisation, SGLT2 inhibitors
Document Type:
Protocol
Author:
NHS England
Target Audience:
Healthcare professionals, clinicians, systems involved in diabetes and heart failure treatment
Period of Validity:
Ongoing
Approval Date:
September 25, 2023
Date of Changes:
Not specified
Clinical Area:
Type 2 diabetes, heart failure, chronic kidney disease
Inclusion Criteria:
Patients aged 18 years and older prescribed empagliflozin, canagliflozin, ertugliflozin, or branded dapagliflozin for T2DM and/or HF
Exclusion Criteria:
Severe renal impairment, diabetic ketoacidosis, and other contraindications as per SPC
Background:
Dapagliflozin is now the first-line SGLT2i in England due to cost reduction following patent expiry.
Implementation Date:
Not specified
Post-switch:
No need for additional eGFR monitoring unless clinical concerns arise
Description:
Protocol outlining the process for switching eligible patients from other SGLT2 inhibitors to dapagliflozin for the management of Type 2 diabetes and heart failure in primary care.
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines optimisation, SGLT2 inhibitors, diabetes, heart failure
Document type:
Protocol
Organ / institution:
NHS England
Author:
NHS
Target audience:
Clinicians, healthcare providers
Period of validity:
Ongoing
Approval date:
Not specified
Modification date:
Not specified
Year:
2014
Region / city:
Australia
Topic:
Pharmaceutical product submission
Document type:
Application for listing
Organization / institution:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target audience:
Health professionals, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
1 April 2014
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines Optimisation, SGLT2 inhibitors
Document Type:
Protocol
Author:
NHS England
Target Audience:
Healthcare professionals, clinicians, systems involved in diabetes and heart failure treatment
Period of Validity:
Ongoing
Approval Date:
September 25, 2023
Date of Changes:
Not specified
Clinical Area:
Type 2 diabetes, heart failure, chronic kidney disease
Inclusion Criteria:
Patients aged 18 years and older prescribed empagliflozin, canagliflozin, ertugliflozin, or branded dapagliflozin for T2DM and/or HF
Exclusion Criteria:
Severe renal impairment, diabetic ketoacidosis, and other contraindications as per SPC
Background:
Dapagliflozin is now the first-line SGLT2i in England due to cost reduction following patent expiry.
Implementation Date:
Not specified
Post-switch:
No need for additional eGFR monitoring unless clinical concerns arise
Description:
Protocol outlining the process for switching eligible patients from other SGLT2 inhibitors to dapagliflozin for the management of Type 2 diabetes and heart failure in primary care.
Year:
2021
Country:
Australia
Drug:
Dapagliflozin
Brand name:
Forxiga
Dosage form and strength:
Tablet, 10 mg
Sponsor:
AstraZeneca Pty Ltd
Indication:
Chronic kidney disease
Submission type:
Category 1 submission
Requested listing:
Authority Required (Streamlined), General Schedule
Regulatory bodies:
Pharmaceutical Benefits Advisory Committee; Therapeutic Goods Administration
Target population:
Adults with chronic kidney disease with specified eGFR and UACR ranges
Comparator:
Placebo plus standard of care
Intervention:
Dapagliflozin plus standard of care
Clinical claims:
Superior efficacy and non-inferior safety versus standard of care alone
Related indications:
Type 2 diabetes mellitus; heart failure with reduced ejection fraction
Regulatory status date:
Priority review granted 13 November 2020
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines optimisation, SGLT2 inhibitors, diabetes, heart failure
Document type:
Protocol
Organ / institution:
NHS England
Author:
NHS
Target audience:
Clinicians, healthcare providers
Period of validity:
Ongoing
Approval date:
Not specified
Modification date:
Not specified
Country:
England
Healthcare system:
National Health Service (NHS)
Issuing body:
NHS England
Medicines mentioned:
Dapagliflozin; Forxiga; Empagliflozin; Canagliflozin; Ertugliflozin
Therapeutic class:
SGLT2 inhibitors
Indications:
Heart failure; Diabetes mellitus
Document type:
Patient information leaflet
Subject:
Change of prescribed SGLT2 inhibitor medication
Dosage information:
10mg once daily; 5mg starting dose in patients with liver problems
Target audience:
Patients prescribed SGLT2 inhibitors for heart failure and/or diabetes
Geographical scope:
England